DE69834828D1 - Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462) - Google Patents

Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)

Info

Publication number
DE69834828D1
DE69834828D1 DE69834828T DE69834828T DE69834828D1 DE 69834828 D1 DE69834828 D1 DE 69834828D1 DE 69834828 T DE69834828 T DE 69834828T DE 69834828 T DE69834828 T DE 69834828T DE 69834828 D1 DE69834828 D1 DE 69834828D1
Authority
DE
Germany
Prior art keywords
agonists
antagonists
construction
igf receptor
binding site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69834828T
Other languages
English (en)
Other versions
DE69834828T2 (de
Inventor
David Bentley
Jane Cosgrove
John Frenkel
Peter Garrett
Jean Lawrence
Meizhen Lou
Oscar Lovrecz
Moreton Mckern
Archibald Tulloch
Wesley Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP0585A external-priority patent/AUPP058597A0/en
Priority claimed from AUPP2598A external-priority patent/AUPP259898A0/en
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of DE69834828D1 publication Critical patent/DE69834828D1/de
Application granted granted Critical
Publication of DE69834828T2 publication Critical patent/DE69834828T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69834828T 1997-11-27 1998-11-27 Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462) Expired - Lifetime DE69834828T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPP0585A AUPP058597A0 (en) 1997-11-27 1997-11-27 Receptor agonists and antagonists
AUPP058597 1997-11-27
AUPP002598 1998-03-25
AUPP2598A AUPP259898A0 (en) 1998-03-25 1998-03-25 EGF receptor family agonists and antagonists
PCT/AU1998/000998 WO1999028347A1 (en) 1997-11-27 1998-11-27 Method of designing agonists and antagonists to igf receptor

Publications (2)

Publication Number Publication Date
DE69834828D1 true DE69834828D1 (de) 2006-07-20
DE69834828T2 DE69834828T2 (de) 2007-01-04

Family

ID=25645663

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834828T Expired - Lifetime DE69834828T2 (de) 1997-11-27 1998-11-27 Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)

Country Status (7)

Country Link
US (1) US7020563B1 (de)
EP (1) EP1034188B1 (de)
JP (1) JP2001525339A (de)
AT (1) ATE328903T1 (de)
CA (1) CA2311926A1 (de)
DE (1) DE69834828T2 (de)
WO (1) WO1999028347A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP380498A0 (en) * 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
WO2000073793A2 (en) * 1999-05-27 2000-12-07 Cecil Yip Identification of compounds modulating insulin receptor activity
JP2004512010A (ja) * 2000-03-29 2004-04-22 ディージーアイ・バイオテクノロジーズ・エル・エル・シー インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト
AU2002257132A1 (en) * 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
CA2490542C (en) 2002-05-23 2013-07-16 Mark I. Greene Fas peptide mimetics and uses thereof
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
MX2007006640A (es) 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
JP2008542685A (ja) * 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
EP2468767B1 (de) 2006-06-22 2015-10-28 Walter and Eliza Hall Institute of Medical Research Struktur der Insulinrezeptor-Ektodomäne
AU2007262666B2 (en) * 2006-06-22 2013-09-12 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
WO2008108986A2 (en) * 2007-03-02 2008-09-12 Amgen Inc. Methods and compositions for treating tumor diseases
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
HUE026374T2 (en) * 2008-12-12 2016-05-30 Boehringer Ingelheim Int Anti-IGF antibody
EP2422201B1 (de) * 2009-04-22 2015-04-22 The Walter and Eliza Hall Institute of Medical Research Struktur der c-endregion der insulinrezeptor-alpha-kette und der alpha-kette des insulinähnlichen wachstumsfaktors
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN107290198B (zh) * 2017-07-25 2019-07-16 中国科学院微生物研究所 一种利用pip对生物材料染色的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927854T2 (de) * 1988-06-30 1997-10-16 Hope City Insulinomimetrische eigenschaften und insulin-rezeptor-bindestellen-peptide
DE69433935D1 (de) * 1993-11-26 2004-09-09 Lawrence B Hendry Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Also Published As

Publication number Publication date
US7020563B1 (en) 2006-03-28
EP1034188B1 (de) 2006-06-07
EP1034188A1 (de) 2000-09-13
EP1034188A4 (de) 2004-12-08
CA2311926A1 (en) 1999-06-10
JP2001525339A (ja) 2001-12-11
ATE328903T1 (de) 2006-06-15
WO1999028347A1 (en) 1999-06-10
DE69834828T2 (de) 2007-01-04
WO1999028347A8 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
DE69834828D1 (de) Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
DE60018907D1 (de) Verfahren und zusammensetzung zur zementierung von bohrlöchern
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE69826705D1 (de) Verfahren zur dermalen verabreichung von polypeptiden
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE69824545D1 (de) Vorrichtung zur abgabe von kabelbindern
DE60026452D1 (de) Verfahren zur Identifizierung von Peptidensequenzen und Proteinensequenzen mittels Massenspektromterie
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE342976T1 (de) Cytokinrezeptor-kette
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
DE59408917D1 (de) Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
ATE384737T1 (de) Verfahren zur reinigung von rekombinanten proteinen, welche wachstumshormon antagonisten sind, mittels wässriger zweiphasen-extraktion
DK0793721T3 (da) Peptider, der er i stand til at binde sig til GAP-proteinets SH3-domæne, nukleotidsekvenser, der koder derfor, fremstilling og anvendelse deraf
DE60136607D1 (de) System und Verfahren zur Lieferung von Karteninformationen
ATE406438T1 (de) Menschliches homolog aus der familie der metalloproteasen
DE69808475T2 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DK1095143T3 (da) Inhibitor til diagnosticering og behandling af patienter med hæmofili A
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE69821826D1 (de) Verfahren und Zusammensetzung zur Zementierung von Bohrlöcher
DK0811068T3 (da) Humane DNase I varianter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RES, AU

8327 Change in the person/name/address of the patent owner

Owner name: THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL, AU